• Trendlyne logo
  • Markets
  • Alerts
  • F&O
  • MF
  • Reports
  • Screeners
  • Subscribe
  • Superstars
  • Portfolio
  • Watchlist
  • Insider Trades
  • Results
  • Data Downloader
  • Events Calendar
  • What's New
  • Explore
  • FAQs
  • Widgets
More
    Search stocks
    IND USA
    IND
    IND
    IND
    USA
    • Stocks
    • Futures & Options
    • Mutual Funds
    • News
    • Fundamentals
    • Reports
    • Corporate Actions
    • Alerts
    • Shareholding
    logo
    Mankind Pharma Ltd.
    10 Feb 2025
    2596.80
    1.03%
    Mankind Pharma Approves Sale Of Entire Stake In Wholly Owned Mahananda Spa And Resorts To Chalet Hotels
    Mankind Pharma Approves Sale Of Entire Stake In Wholly Owned Mahananda Spa And Resorts To Chalet Hotels
    NDTV Profit
    The enterprise value of the deal is Rs 530 crore and the transaction is expected to be completed by Feb. 28.
    Copy LinkShare onShare on Share on Share on
    Mankind Pharma Ltd. is trading above all available SMAs
    logo
    AstraZeneca Pharma India Ltd.
    10 Feb 2025
    9058.50
    -0.87%
    AstraZeneca's cancer drug tops list of new brands launched in 2024
    Business Standard
    Indicates growing incidence of cancer among Indian population; five out of top 20 new brand launches are cancer drugs
    Copy LinkShare onShare on Share on Share on
    Number of MF schemes increased from 53 to 60 in Jun 2025 qtr.
    logo
    AstraZeneca Pharma India Ltd.
    10 Feb 2025
    9058.50
    -0.87%
    AstraZeneca Pharma India Gets Warning Letter From NSE
    AstraZeneca Pharma India Gets Warning Letter From NSE
    NDTV Profit
    The warning letter was issued to AstraZeneca Pharma India for not complying with a regulatory norm that mandates the attendance of at least two independent directors in audit committee meeting.
    Copy LinkShare onShare on Share on Share on
    AstraZeneca Pharma India Ltd. is trading above all available SMAs
    logo
    Sanofi Consumer Healthcare India Ltd.
    10 Feb 2025
    5205.50
    -1.18%
    Sanofi gets the green light to sell transplant-related drug Rezurock, in India
    Business Line
    Rezurockwas approved by the regulatory United States Food and Drug Administration, and India's CDSCO (Central Drugs Standard Control Organisation)
    Copy LinkShare onShare on Share on Share on
    Number of FII/FPI investors decreased from 136 to 114 in Jun 2025 qtr
    logo
    Morepen Laboratories Ltd.
    10 Feb 2025
    54.07
    0.58%
    Volume shocker: Morepen Labs falls 18% as nearly 8 mn shares change hands
    Business Standard
    Morepen Labs share price: Volumes on the Morepen Labs counter jumped suddenly around 1:05 PM with around 1.67 million shares changing hands in multiple tranches on the BSE
    Copy LinkShare onShare on Share on Share on
    Morepen Laboratories Ltd. has gained 16.56% in the last 1 Month
    logo
    Alkem Laboratories Ltd.
    07 Feb 2025
    5475.00
    0.05%
    Alkem Labs announces acquisitions in skincare and medical devices segments
    Business Line
    To acquire 100% stake in Adroit Biomed, a pharmaceutical company focussed on the skincare segment, for around 140 crore
    Copy LinkShare onShare on Share on Share on
    Alkem Laboratories L.. has an average target of 5296.00 from 2 brokers.
    Alkem Laboratories Q3 net profit rises 5.2%, revenue sees marginal growth
    Business Standard | 07 Feb 2025 1 more
    Alkem Labs Q3 Results: Net profit rises just 6% to 641 crore, total income flat; stock declines 4%
    livemint | 07 Feb 2025
    logo
    Akums Drugs & Pharmaceuticals Ltd.
    07 Feb 2025
    472.60
    0.25%
    Akums Drugs and Pharma Q3 Results: Adjusted Profit Rises 15% To Rs 66.3 Crore
    Akums Drugs and Pharma Q3 Results: Adjusted Profit Rises 15% To Rs 66.3 Crore
    NDTV Profit
    Adjusted profit is calculated as the profit for the quarter/period plus fair value changes to financial instruments less tax impact on account of business merger, the filing said.
    Copy LinkShare onShare on Share on Share on
    Akums Drugs & Pharmaceuticals Ltd.'s price crossed below 30Day SMA today
    Akums Drugs slips 3% after posting 66% decline in Q3 profits, rev down 7%
    Business Standard | 07 Feb 2025
    logo
    Wockhardt Ltd.
    07 Feb 2025
    1533.60
    -0.94%
    Wockhardt Q3 Results: Pharma Major Swings Back To Profit As Expenses Fall
    Wockhardt Q3 Results: Pharma Major Swings Back To Profit As Expenses Fall
    NDTV Profit
    On the operating side, Ebitda jumped 84.6% to Rs 96 crore, while margin expanded to 13.3% from 7.4%.
    Copy LinkShare onShare on Share on Share on
    Wockhardt Ltd. is trading above its 200 day SMA of 1468.4
    logo
    Cipla Ltd.
    07 Feb 2025
    1567.20
    0.49%
    Cipla stock shows strength on charts, adopt Bull Spread: Nandish Shah
    Business Standard
    Cipla share price: The short-term trend turned positive as Cipla stock price closed above its 5 and 11 day EMA
    Copy LinkShare onShare on Share on Share on
    Cipla Ltd. has an average target of 1702.60 from 10 brokers.
    logo
    Aurobindo Pharma Ltd.
    06 Feb 2025
    1102.90
    0.66%
    Aurobindo Pharma Q3FY25 results: PAT falls 10% to Rs 845.56 crore
    Business Standard
    Company board approves purchase of 80 per cent share in step-down subsidiary Tergene Biotech
    Copy LinkShare onShare on Share on Share on
    Aurobindo Pharma Ltd. has lost -28.96% in the last 1 Year
    Aurobindo Pharma Q3 Results: Profit Falls 9.7%, Misses Estimates
    NDTV Profit | 06 Feb 2025
    more
    loading
    Trendlyne Logo Trendlyne
    Stay ahead of the market
    Markets Today
    • Nifty 50 today
    • Sensex today
    • Latest Quarterly results
    • FII & DII data today
    Dashboard
    • Industry & Sector analysis
    • ETFs
    • Mutual Funds
    • Bullish & Bearish spread
    • Global Indices
    Tools
    • Compare stocks
    • Widgets
    • Data Downloader
    • Excel Connect
    IPOs
    • Dashboard (Mainboard & SME)
    • Upcoming IPOs
    • Recently Listed IPOs
    • Most Successful IPOs
    Upcoming IPOs
    • Vms Tmt
    • Sampat Aluminium
    • Euro Pratik Sales
    Quick Links
    • Contact us
    • Blogs
    • FAQs
    Company
    • Privacy
    • Terms of Use
    • Disclaimer
    Trendlyne Products
    • Starfolio
    • SmartOptions
    • Trendlyne US Global
    Get Mobile App
    • Android
    • iOS

    Copyright © 2025 Giskard Datatech Pvt Ltd